Boston Scientific takes a non-cash $3.4 billion impairment of goodwill charge to its bottom line over weakening economic conditions, sending the medical device company to a loss for the quarter; DES, CRM and ICD sales slump badly in the quarter as 2012 outlook lowered.
Boston Scientific (NYSE:BSX) swung to a $3.4 billion loss, lowered its year-end guidance and saw its bread and butter businesses drop by double-digit percentage points during a tough 2nd quarter for the medical device company.
Hologic wins FDA approval for its new C-View 2D imaging software for use with its 3D breast...
The hallowed emerging markets in Brazil, Russia, India and China aren't generating the kind of growth...
Medical device company Bausch + Lomb won FDA approval for its Trulign Toric intraocular lens, the 1st...
California medical device maker Claret Medical's embolic protection technology captures debris...
Texas-based Galt Medical Corp. is reportedly laying off 139 workers as it shutters its hometown plant...